Comparison of HER2-Targeted Antibodies for Fluorescence-Guided Surgery in Breast Cancer

Figure 1

Flow cytometry analysis of IRDye800-immunocojugate binding in HER2-postive (BT474) and HER2-negative (MCF7) cells. HER2-specific binding was observed for trastuzumab-IRDye800 and pertuzumab-IRDye800 as indicated by a shift of the fluorescence signal to the right in BT474 cells compared to the lower fluorescence values measured from MCF7 cells (a). Plot of the MFI values of BT474 cells incubated with the immuoconjugates and the blocking doses of the unconjugated parental antibodies (b).

(a)

(b)